Loading clinical trials...

Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy | Clinical Trials | Clareo Health

UNKNOWNPHASE2

Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy

Open Prospective Clinical Trial to Develop the Computer Software (Intelligent Prognostic System) for Predicting the Efficacy of Anti-PD-1 Immunotherapy of Melanoma Patients in Routine Practice

NCT04928365•Blokhin's Russian Cancer Research Center

View on ClinicalTrials.gov

Summary

Open prospective clinical trial to develop the computer software (Intelligent prognostic system) for predicting the efficacy of anti-PD-1 immunotherapy of melanoma patients in routine practice

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Morphological verification of cutaneous melanoma. Verification of metastases is not necessary
•2. ECOG 0-1
•3. Age of patients - 18 years and older
•4. No prior chemotherapy, immunotherapy, radiation or hormonal therapy
•5. Adequate contraception for women of childbearing age
•6. Written consent of the patient to participate in the study

Exclusion Criteria

•1. Non-compliance with the previously listed criteria
•2. Pregnancy and breastfeeding
•3. Therapy with systemic corticosteroids and/or other immunosuppressants within 4 weeks before the screening or a high probability of the need for their use during the study for the treatment of intercurrent pathology
•4. History of another malignancy other than the study indication under this trial within 5 years of study enrollment. Does not apply to subjects who underwent successful definitive resection of basal or squamous cell carcinoma of the skin, in situ cervical cancer, in situ breast cancer, or other in situ cancers.

Locations (1)

N.N. Blokhin Russian Cancer Research Center, Kashirskoye shosse 23

Moscow, Russia

Key Dates

Start Date

March 25, 2021

Primary Completion Date

May 11, 2021

Completion Date

March 25, 2023

Last Updated

June 16, 2021

Enrollment

ESTIMATED participants

Conditions

Melanoma

Interventions

Anti-PD-1 monoclonal antibody

DRUG

Contacts

Irina N Mikhaylova, DSc

CONTACT

8 499 324 90 24 irmikhaylova@gmail.com

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

RECRUITINGPHASE1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 16, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy

Inclusion Criteria

Exclusion Criteria

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma